Skip to main content
Premium Trial:

Request an Annual Quote

CardioDx Raises $35M

NEW YORK (GenomeWeb) – CardioDx today announced the close of a $35 million financing round.

The funds will be used to expand the commercial use of Corus CAD and to support the company's development of other genomic tests for coronary artery disease, CardioDx said. Corus CAD is a gene expression-based test for assessing non-diabetic patients who display symptoms suggestive of obstructive CAD. 

Along with CardioDx's existing investors, Alberta Investment Management participated in the round.  

In July the Redwood City, Calif.-based company said in a regulatory document that it raised $21 million toward a targeted goal of $25 million. The $35 million figure includes the July financing. 

CardioDx filed for an initial public offering in October 2013 but has not gone public yet.

 

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.